secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tempest Therapeutics, Inc. (TPST)
CIK:        0001544227
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070416
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tempest Q1 net loss $10.9M; cash $21.5M; exploring strategic alternatives
-------------------------------------------------------------------------

- Cash and equivalents $21.5M at March 31, 2025, down from $30.3M at Dec 31, 2024.
- Net loss $10.9M ($3.16/share) vs $7.9M ($4.62/share) in Q1 2024; R&D expense $7.6M.
- Completed workforce reduction on April 30, 2025; repaid $3.5M loan to Oxford Finance.
- FDA granted Orphan Drug and Fast Track designations for amezalpat in HCC.
- TPST-1495 granted Orphan Drug for FAP; FDA allowed Phase 2 trial to proceed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/0000950170-25-070416-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1544227/000095017025070416/tpst-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070416

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer